Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 229

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 229
---
 the Selling Shareholder's commitment to purchase common shares under the SEPA) are being registered for resale under the registration statement that includes this prospectus. While the Company expects that such 7,500,000 common shares, when combined with those 1,890,000 common shares previously issued to the Selling Shareholder pursuant to the Prior Registration Statement, would be sufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling Shareholder equal to the Selling Shareholder's $15,000,000 total aggregate purchase commitment under the SEPA, such proceeds will ultimately depend on the market conditions and the actual sale price of the common shares to the Selling Shareholder at the time of issuance. Since the market price of our common shares may fluctuate from time to time after the date of this prospectus and, as a result, the actual purchase price to be paid by the Selling Shareholder under the SEPA for common shares, if any, may also fluctuate, in order for us to receive the full amount of the Selling Shareholder's commitment under the SEPA, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that includes this prospectus.

If it becomes necessary for us to issue and sell to the Selling Shareholder more shares than are being registered for resale under this prospectus in order to receive aggregate gross proceeds of $15,000,000 under the SEPA, we must first file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Shareholder of any such additional common shares, which the SEC must declare effective, in each case, before we may elect to sell any additional common shares to the Selling Shareholder under the SEPA. The number of common shares ultimately offered for resale by the Selling Shareholder depends upon the number of common shares, if any, we ultimately sell to the Selling Shareholder under the SEPA.

<div align='center'>151</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

The issuance, if any, of common shares to the Selling Shareholder pursuant to the SEPA would not affect the rights or privileges of our existing shareholders, except that the economic and voting interests of each of our existing shareholders would be diluted. Although the number of common shares that our existing shareholders own would not decrease as a result of sales